Pectoreal develops tissue-engineered breast implants designed to reduce complications and improve quality of life for breast cancer survivors and cosmetic patients. The company's Pectofil and Pectograft implants are reverse-engineered from natural breast tissue, enabling minimally immunogenic, off-the-shelf products that can be implanted during the same procedure as a mastectomy. This single-operation approach aims to reduce hospital stays, repeat surgeries, and long-term healthcare costs.
Funding
Funding not disclosed
Founders
Product
Problem
Current breast reconstruction options—autologous tissue flaps and synthetic implants—carry substantial drawbacks, including high failure rates, need for repeat operations, long hospitalizations, and psychological trauma for patients. Many women who test positive for BRCA or undergo mastectomy face difficult trade-offs between quality of life and surgical risk, and there are no existing products with good clinical outcomes for managing cases post-lumpectomy.
Solution
Pectoreal is developing two classes of natural breast implants—Pectofil and Pectograft—using tissue-engineered technology that reverse-engineers adipose tissue in the lab to promote regeneration of natural breast tissue after implantation. The implants are designed to be minimally immunogenic, becoming part of the breast naturally with blood supply and sensation restored. They can be implanted in a single operation at the same time as the primary mastectomy or lumpectomy, reducing surgical complications, hospital days, and the need for repeat procedures. The technology aims to restore both cosmesis and sensation, which are vital for the psychological and social wellbeing of cancer survivors.
Target Audience
Primary customers are breast cancer patients undergoing mastectomy or lumpectomy who seek reconstructive surgery, as well as plastic surgeons and healthcare providers looking for safer, more natural implant alternatives. The technology also targets cosmetic patients seeking breast augmentation and other aesthetic procedures.
Features
- Tissue-engineered implants derived from reverse-engineered natural breast tissue, designed to be minimally immunogenic and integrate naturally with blood supply and sensation
- Single-procedure implantation during the same operation as mastectomy or lumpectomy, reducing risk of surgical complications and hospital stay duration
- Off-the-shelf product availability designed for two clinical presentations: post-lumpectomy and post-radical mastectomy
- Reduced complication rates compared to synthetic implants, lowering long-term medical costs
- Technology applicable beyond breast reconstruction to aesthetic and reconstructive procedures including breast augmentation, reconstructive rhinoplasty, facelift, thigh lift, buttock lift, and vaginal reconstruction